Amer M. Zeidan

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 519 citations · Full text

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Akshay Sharma, Neel S. Bhatt, Andrew St. Martin et al. · The Lancet Haematology · 2021 · 357 citations · Full text

Transplantation, Marrow Transplantation, Clinical Characteristics +11

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2016 · 293 citations

Hematological Malignancy, Oncology, Diagnostic Classification +14

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein et al. · The Lancet Oncology · 2021 · 185 citations

Phase 1B, Hematological Malignancy, Azacitidine Versus Azacitidine +8

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein et al. · Journal of Clinical Oncology · 2020 · 170 citations · Full text